查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1931223

妇科避孕植入市场（按产品、最终用户和分销管道划分），全球预测，2026-2032年

Gynecological Contraceptive Implant Market by Product, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，妇科避孕植入市场价值将达到 4.5094 亿美元，到 2026 年将成长至 4.7552 亿美元，到 2032 年将达到 6.5719 亿美元，复合年增长率为 5.52%。

关键市场统计数据
基准年 2025 4.5094亿美元
预计年份：2026年 4.7552亿美元
预测年份 2032 6.5719亿美元
复合年增长率 (%) 5.52%

综合考虑避孕植入的临床意义、相关人员的责任以及对护理路径和病人历程。

避孕植入已成为众多生殖健康工具中的佼佼者，它经久耐用，由医护人员操作，能够持续释放激素，并提供可预测的避孕效果。这些装置越来越多地应用于计划生育诊所、全科诊所、医院以及青少年和妇女专科中心等临床诊疗流程中，由此引发了一系列除了产品性能之外的运营和临床考量，包括培训、库存管理和患者咨询。

简要概述临床创新、数位医疗服务和政策调整如何整合，从而重新定义产品采用路径和服务经济。

避孕植入市场正受到临床、技术和政策变革的共同影响，这些变革正在重新定义产品开发和服务提供方式。器械设计和荷尔蒙配方方面的进步，以及关于长期使用和怀孕復发率的新证据，促使临床医生和指南制定者重新评估咨询框架和植入通讯协定。因此，临床实践正朝着更个人化的避孕方案转变，这些方案会考虑患者的生命週期并兼顾其合併的疾病。

对 2025 年实施的关税对整个植入供应链的采购、购买和服务成本的影响进行客观分析。

美国2025年关税政策对避孕植入物组件和成品引入了新的进口规定，对生产、分销和采购管道产生了广泛影响。这些关税提高了从受影响地区采购的产品和原材料的到岸成本，促使製造商评估替代采购方案并重新考虑其定价策略。因此，医院、诊所和专科医疗中心的采购团队在评估植入项目的总拥有成本（TCO）时，面临更严格的谈判和审查。

基于细分市场的详细分析，将营运影响与产品化学、临床环境、通路以及按年龄组分類的患者优先事项联繫起来

产品細項分析揭示了两种主要植入化学成分在临床和商业性的显着差异。依托孕烯植入定位为长效避孕药，具有成熟的医护人员认知度和规范的追踪通讯协定；而levonorgestrel植入则常用于需要其他激素组合且对成本敏感的采购场景。这些产品特性会影响临床医生的培训需求、咨询服务以及不同临床环境下的库存规划。

区域比较分析：说明监管差异、卫生系统结构和区域准入优先事项如何影响全球植入交付。

区域趋势正在以不同的方式影响美洲、欧洲、中东和非洲以及亚太地区的监管流程、支付方参与和服务提供结构。在美洲，综合医疗系统和大规模私人医疗服务网络推动了密集的采购週期和集中式培训项目，而该地区多样化的公共卫生倡议则侧重于扩大服务覆盖范围和分担任务，以提高避孕药具的可及性。

策略性企业因应措施和竞争定位的核心在于：优先考虑临床证据、拓展通路，并透过强大的供应链体系促进产品的广泛应用。

避孕植入领域的主要企业正致力于透过配方创新、提升易用性以及提供全生命週期支援服务来增强产品差异化优势。这些企业优先考虑产生可靠的临床证据并参与指南制定，以增强临床可信度，并为医保报销谈判奠定基础。与医疗服务提供者网路和专业协会的策略合作正在拓展培训倡议，并支持收集真实世界结果数据，最终有助于推动产品的普及应用。

为製造商、医疗服务提供者和支付方提供切实可行的策略，以加强证据支持、拓展通路、增强供应链韧性并改善医疗服务可及性。

产业领导者应将临床证据的产生与有针对性的医护人员教育计画结合，以促进信任和合理使用。对实用性试验和上市后监测的投入能够加强支持指南发布和医保支付方讨论的证据基础，而结构化的植入和取出培训项目则能提高医护人员的信心并改善患者预后。这些措施能够减少诊疗过程中的摩擦，并支持可持续的服务提供。

采用严谨的混合调查方法，结合相关人员访谈、临床指引综合和供应链图谱分析，得出检验的营运洞察。

本研究基于检验基础，采用混合方法，结合对临床医生、采购主管和支付方代表的定性访谈，以及对临床指南、监管文件和同行评审文献的系统性回顾。供应链图谱和分销管道分析纳入了製造商资讯披露的资讯、竞标资讯以及机构买家可观察的库存管理实践，从而能够深入了解物流限制因素和营运解决方案。

这项研究是一项实用性综合研究，强调临床疗效必须与营运准备和商业性协调相结合，才能确保持续的可及性和影响力。

本概要中概述的融合趋势表明，未来避孕植入将融入多元化的医疗服务路径，并以更强有力的临床证据、数位互动工具和适应性分销模式为支持。营运韧性、临床医生培训以及与支付方优先事项的契合度将决定创新能否带来持续的可及性和更好的患者疗效。简而言之，仅靠技术性能并不能保证推广应用；实施机制和商业性契合度同样至关重要。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 妇科避孕植入市场（依产品分类）

  • 依托孕烯植入
  • levonorgestrel植入

9. 依最终使用者分類的妇科避孕植入市场

  • 诊所
  • 医院
    • 私立医院
    • 公立医院
  • 专业医疗中心

10. 妇科避孕植入市场（依通路划分）

  • 离线
  • 在线的

11. 各地区妇科避孕植入市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

12. 妇科避孕植入市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

13. 各国妇科避孕植入市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

14. 美国妇科避孕植入市场

第十五章 中国妇科避孕植入市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Actavis plc
  • Agile Therapeutics, Inc.
  • Allergan plc
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Evofem Biosciences, Inc.
  • Gilead Sciences, Inc.
  • HRA Pharma
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Warner Chilcott plc
Product Code: MRR-7B550E008DCB

The Gynecological Contraceptive Implant Market was valued at USD 450.94 million in 2025 and is projected to grow to USD 475.52 million in 2026, with a CAGR of 5.52%, reaching USD 657.19 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 450.94 million
Estimated Year [2026] USD 475.52 million
Forecast Year [2032] USD 657.19 million
CAGR (%) 5.52%

An integrated orientation to contraceptive implant clinical relevance, stakeholder responsibilities, and operational implications across care pathways and patient journeys

Contraceptive implants have emerged as a durable, clinician-administered option within the broader spectrum of reproductive health tools, delivering sustained hormone release and predictable contraceptive efficacy. These devices increasingly intersect with clinical pathways spanning family planning clinics, general practice, hospitals, and specialized youth and women's health centers, creating a set of operational and clinical considerations that extend beyond product performance to encompass training, inventory management, and patient counseling.

Clinicians and health systems are balancing clinical benefits against logistics such as insertion and removal capacity, follow-up protocols, and reimbursement models. Concurrently, patients evaluate implants in the context of contraceptive choice, side effect profiles, and long-term reproductive planning. Consequently, stakeholders must interpret clinical trial data alongside real-world evidence, payer practices, and shifting patient preferences to inform procurement, policy, and service delivery.

This summary synthesizes critical developments shaping contraceptive implant adoption, captures structural market shifts, and highlights operational levers that can be applied by manufacturers, providers, payers, and policy makers. It is intended to support strategic decision-making by presenting an integrated view of product types, care settings, distribution channels, regulatory pressures, and demographic patterns that influence access and utilization.

A concise synthesis of how clinical innovation, digital care delivery, and policy adjustments are jointly redefining product adoption pathways and service economics

The landscape for contraceptive implants is being reshaped by converging clinical, technological, and policy shifts that redefine product development and service delivery. Advances in device design and hormone formulations are paired with emerging evidence on extended-duration use and return-to-fertility profiles, prompting clinicians and guideline bodies to reassess counseling frameworks and insertion protocols. As a result, clinical practice is moving toward more individualized contraceptive planning that accounts for patient lifecycle considerations and coexisting medical conditions.

Digital health and telemedicine are exerting an outsized influence on patient engagement and follow-up care. Remote counseling, appointment triage, and digital adherence supports are smoothing access barriers while enabling more efficient clinic workflows. At the same time, distribution models are diversifying: pharmacy-based services and online information platforms are expanding points of access and shifting the locus of patient education. Consequently, manufacturers and providers are increasingly investing in digital materials, training platforms, and partnerships that bridge clinical and community settings.

Policy and regulatory changes are also catalyzing transformation. Greater emphasis on reproductive health equity and updated reimbursement codes in several jurisdictions are altering service economics, while supply chain resilience investments are prompting re-evaluation of sourcing and inventory strategies. Taken together, these shifts demand integrated commercial and clinical responses that align product portfolios, go-to-market approaches, and provider education initiatives with emerging patterns of care and patient expectations.

A clear-eyed assessment of how 2025 tariff measures have reshaped sourcing, procurement, and service delivery costs across implant supply chains

Tariff policy enacted in the United States in 2025 has introduced additional import considerations for components and finished contraceptive implants, creating pervasive effects across manufacturing, distribution, and procurement channels. These duties have raised landed costs for products and inputs sourced from affected jurisdictions, prompting manufacturers to evaluate sourcing alternatives and to reassess pricing strategies. In turn, procurement teams at hospitals, clinics, and specialty centers have faced tighter negotiations and increased scrutiny of total cost of ownership for implant programs.

Supply chain adaptation has been a consistent response. Manufacturers with diversified supplier networks accelerated qualification of secondary suppliers and increased regional warehousing to mitigate duty exposure and reduce lead-time risk. Meanwhile, some buyers adopted longer-term contracting approaches to stabilize supply and manage cost volatility. These operational responses have implications for inventory turnover, capital tied up in stock, and the agility of clinical services to respond to demand fluctuations.

At the clinical interface, increased input costs can affect service delivery decisions; healthcare organizations have had to reconcile budgetary pressures with commitments to access and quality. In some instances, administrators have prioritized training and retention of insertion-capable staff to preserve service volume despite cost headwinds. Importantly, the cumulative impact of tariff-related cost shifts has heightened the incentive for stakeholders to pursue value-based purchasing, local manufacturing partnerships, and policy engagement to reduce trade-related friction and protect access to long-acting reversible contraceptive options.

A nuanced segmentation-driven narrative that connects product chemistries, care settings, distribution pathways, and age-based patient priorities to operational implications

Insights drawn from product segmentation reveal distinct clinical and commercial dynamics for the two principal implant chemistries. Etonogestrel implants are often positioned for long-acting contraception with established provider familiarity and structured follow-up protocols, while levonorgestrel implants are frequently considered when alternative hormonal profiles or cost-sensitive procurement objectives apply. These product distinctions influence clinician training needs, counseling narratives, and inventory planning across care settings.

When viewed through the lens of end users, clinics, hospitals, and specialty centers present different operational realities. Family planning and general clinics prioritize high-throughput counseling and efficient same-day insertion workflows; hospitals, whether private or public, focus on integrated perioperative and outpatient services where implants may be part of broader reproductive health offerings; and specialty centers such as women's health and youth-focused clinics tailor services to specific demographic or clinical needs, emphasizing privacy, continuity of care, and age-appropriate counseling. Each end-user archetype drives particular purchasing behaviors and support requirements from manufacturers.

Distribution channel segmentation further refines access pathways. Hospital pharmacies serve institutional inventory and clinician-administered services, retail pharmacies-both chain and independent-support community access often linked to prescription fulfillment and counseling touchpoints, and online pharmacies operating via manufacturer websites or third-party platforms facilitate broader reach and informational resources that can supplement clinical engagement. Finally, demographic segmentation by age groups from mid-adolescence through the early 40s highlights differing contraceptive priorities, adherence considerations, and counseling emphases, with younger cohorts often prioritizing reversible and low-maintenance options while older cohorts may weigh long-term planning and return-to-fertility timelines.

A comparative regional analysis explaining how regulatory diversity, health system structure, and local access priorities influence implant delivery across global geographies

Regional dynamics shape regulatory processes, payer interactions, and service delivery architectures in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated health systems and large private provider networks drive concentrated procurement cycles and centralized training programs, while diverse public health initiatives in the region emphasize access expansion and task-sharing to enhance contraceptive availability.

Across Europe, the Middle East & Africa, heterogeneous regulatory regimes and variable infrastructure capacity create a mosaic of access models. High-income European markets emphasize reimbursement complexity and clinician credentialing for insertion, whereas many countries within the broader Middle East and Africa region prioritize capacity building, decentralized service delivery, and donor-supported programs to extend reach into underserved populations. These contrasts influence manufacturer go-to-market strategies and clinical training investments.

Asia-Pacific markets combine rapid adoption pathways in urban centers with ongoing access challenges in rural areas. Regulatory timelines and local manufacturing incentives can accelerate product registration and distribution in some economies, while in others, complex import procedures and variable payer coverage require adaptive distribution models. Across regions, stakeholders increasingly weigh regional partnerships, localized education programs, and supply chain resilience initiatives to reconcile global production footprints with local access imperatives.

Strategic corporate responses and competitive positioning that prioritize clinical evidence, channel diversification, and resilient supply operations to drive adoption

Leading firms in the contraceptive implant space are concentrating efforts on enhancing product differentiation through formulation innovation, ease-of-use improvements, and lifecycle support services. Companies prioritize robust clinical evidence generation and guideline engagement to reinforce clinical confidence and inform reimbursement discussions. Strategic collaboration with provider networks and professional societies amplifies training initiatives and supports real-world outcomes data collection that, in turn, supports adoption.

Commercial strategies emphasize channel diversification and patient-centered value propositions. Firms are expanding beyond traditional provider-focused sales models to incorporate digital education, co-pay support, and enhanced warranty or replacement programs. Supply chain strategies have become more resilient through supplier qualification, localized assembly, and expanded safety stock holdings, balancing cost efficiency against service continuity.

Competitive dynamics also reflect a tightening regulatory environment and higher barriers for new entrants, prompting incumbents to pursue incremental innovation, strategic alliances, or targeted acquisitions to fill portfolio gaps. Across the board, successful companies deploy cross-functional coordination between clinical affairs, regulatory, supply chain, and commercial teams to accelerate field adoption while maintaining compliance and quality standards.

Actionable strategies for manufacturers, providers, and payers to strengthen evidence, diversify channels, and build supply resilience while improving access

Industry leaders should align clinical evidence generation with targeted provider education programs to accelerate trust and appropriate utilization. Investing in pragmatic trials and post-market surveillance enhances the evidence base that supports guideline inclusion and payer discussions, while structured training programs for insertion and removal improve provider confidence and patient outcomes. These measures reduce friction at the point of care and support sustained service delivery.

Diversifying distribution options and reinforcing supply chain resilience will limit exposure to trade and logistical disruptions. Establishing secondary sources for critical components, regional warehousing, and flexible contracting with key buyers can reduce lead-time variability and price pressure. Simultaneously, manufacturers and suppliers should strengthen partnerships with pharmacy networks and digital platforms to expand access while ensuring clinical oversight and counseling resources are available.

Finally, aligning commercial models with value-based procurement principles will help reconcile cost pressures with access goals. Offering bundled training, outcome monitoring, and outcome-based contracting mechanisms where feasible creates shared incentives for quality care. Leaders should also proactively engage with policymakers and payer groups to articulate the population health benefits of long-acting contraceptive options and to inform reimbursement frameworks that support equitable access.

A rigorous mixed-methods methodology combining stakeholder interviews, clinical guideline synthesis, and supply chain mapping to produce validated operational insights

This research draws upon a mixed-methods approach combining primary qualitative interviews with clinicians, procurement leaders, and payer representatives, together with systematic review of clinical guidelines, regulatory filings, and peer-reviewed literature to construct a validated evidence base. Supply chain mapping and distribution channel analysis were informed by manufacturer disclosures, procurement tenders, and observable inventory practices at institutional buyers, enabling a pragmatic view of logistical constraints and operational responses.

Data triangulation was applied to reconcile differences between clinical efficacy data and real-world utilization patterns, integrating insights from professional society recommendations, training curricula, and outcome registries. Stakeholder interviews were structured to explore adoption barriers, reimbursement dynamics, and clinical workflow impacts, while methodological safeguards included multiple coder validation, source cross-referencing, and transparency about data limitations.

Limitations include variability in reporting standards across jurisdictions and the evolving nature of tariff and trade policy. To mitigate these, the analysis emphasizes structural drivers and demonstrable operational responses rather than speculative projections. The methodology supports robust, actionable conclusions by emphasizing reproducibility, stakeholder validation, and clear linkage between evidence and recommended actions.

A pragmatic synthesis emphasizing that clinical efficacy must be paired with operational readiness and commercial alignment to secure lasting access and impact

The convergent trends outlined in this summary point to a future where contraceptive implants are integrated into diversified care pathways supported by enhanced clinical evidence, digital engagement tools, and adaptive distribution models. Operational resilience, clinician training, and alignment with payer priorities will determine whether innovations translate into sustained access and improved patient outcomes. In short, technical performance alone will not assure adoption; implementation mechanics and commercial alignment are equally pivotal.

Stakeholders that invest in coordinated evidence generation, provider enablement, and supply chain flexibility will be best positioned to navigate policy shifts and cost pressures while preserving access. By focusing on pragmatic interventions-such as targeted training, secondary sourcing, and collaboration with community pharmacies-organizations can reduce friction and expand equitable reach. The combined emphasis on clinical rigor and operational practicality offers a clear path to strengthening the role of implants within comprehensive reproductive health services.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gynecological Contraceptive Implant Market, by Product

  • 8.1. Etonogestrel Implant
  • 8.2. Levonorgestrel Implant

9. Gynecological Contraceptive Implant Market, by End User

  • 9.1. Clinic
  • 9.2. Hospital
    • 9.2.1. Private Hospital
    • 9.2.2. Public Hospital
  • 9.3. Specialty Center

10. Gynecological Contraceptive Implant Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Gynecological Contraceptive Implant Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Gynecological Contraceptive Implant Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Gynecological Contraceptive Implant Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Gynecological Contraceptive Implant Market

15. China Gynecological Contraceptive Implant Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Actavis plc
  • 16.6. Agile Therapeutics, Inc.
  • 16.7. Allergan plc
  • 16.8. Amgen Inc.
  • 16.9. AstraZeneca PLC
  • 16.10. Bayer AG
  • 16.11. Bristol-Myers Squibb Company
  • 16.12. Eli Lilly and Company
  • 16.13. Evofem Biosciences, Inc.
  • 16.14. Gilead Sciences, Inc.
  • 16.15. HRA Pharma
  • 16.16. Johnson & Johnson
  • 16.17. Merck & Co., Inc.
  • 16.18. Mylan N.V.
  • 16.19. Novartis AG
  • 16.20. Novo Nordisk A/S
  • 16.21. Pfizer Inc.
  • 16.22. Roche Holding AG
  • 16.23. Sanofi S.A.
  • 16.24. Sun Pharmaceutical Industries Ltd.
  • 16.25. Takeda Pharmaceutical Company Limited
  • 16.26. Teva Pharmaceutical Industries Ltd.
  • 16.27. Warner Chilcott plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY ETONOGESTREL IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY ETONOGESTREL IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY ETONOGESTREL IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY LEVONORGESTREL IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY LEVONORGESTREL IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY LEVONORGESTREL IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY SPECIALTY CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY SPECIALTY CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. AMERICAS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 35. AMERICAS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 36. AMERICAS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 39. NORTH AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. NORTH AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 41. NORTH AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. LATIN AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. LATIN AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 46. LATIN AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 50. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. MIDDLE EAST GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 61. MIDDLE EAST GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 66. AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. ASEAN GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. ASEAN GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 77. ASEAN GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. GCC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GCC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 82. GCC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GCC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 84. GCC GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPEAN UNION GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPEAN UNION GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPEAN UNION GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. BRICS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. BRICS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 92. BRICS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. G7 GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. G7 GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 97. G7 GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. G7 GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 99. G7 GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NATO GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NATO GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 102. NATO GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NATO GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 104. NATO GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. UNITED STATES GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. UNITED STATES GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 108. UNITED STATES GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. CHINA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. CHINA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 113. CHINA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA GYNECOLOGICAL CONTRACEPTIVE IMPLANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)